Using neutrophil nanovesicles to deliver drugs for lung inflammation treatment
Active Drug Loading to Nanovesicles for Targeted Drug Delivery
This study is exploring a new way to help people with lung inflammation from bacterial infections by using tiny particles made from immune cells to deliver medicine right where it's needed, which could lead to better treatments for conditions like acute respiratory distress syndrome (ARDS).
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington State University NIH-funded |
| Lab location | 1 site (Pullman, United States) |
| Project ID | NIH-10579817 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treat acute lung inflammation caused by bacterial infections. By creating nanovesicles from neutrophil membranes, the study aims to develop a targeted drug delivery system that can effectively transport medications directly to inflamed lung tissues. The methodology involves using mouse models to test the efficacy of these nanovesicles in reducing inflammation and improving lung function. Patients may benefit from advancements in treatment options for conditions like acute respiratory distress syndrome (ARDS).
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who are experiencing acute lung inflammation or related bacterial infections.
Not a fit: Patients with chronic lung conditions or those not experiencing acute inflammation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from severe lung inflammation and related complications.
How similar studies have performed: While the use of nanovesicles for drug delivery is a growing field, this specific approach targeting lung inflammation is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
Pullman, United States
- Washington State University — Pullman, United States (Active)
Researchers
- Principal investigator: Wang, Zhenjia — Washington State University
- Study coordinator: Wang, Zhenjia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.